Targacept (TRGT) revises top-line results from exploratory Phase 2 study of TC-6987 in asthma, found error in app
Tweet
Share
E-mailGet Alerts TRGT Hot Sheet
Join SI Premium – FREE
Targacept (Nasdaq: TRGT) revises top-line results from exploratory Phase 2 study of TC-6987 in asthma, found error in app
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
